Shilpa Medicare Limited (SHILPAMED) — Announcement
Shilpa Medicare announced that its material subsidiary Shilpa Biologicals received an upgraded credit rating of IND A+ from India Ratings and Research, with a Stable outlook, reflecting improved financial health and lower default risk for its bank facilities. This rating action signals stronger creditworthiness for the subsidiary, which may enhance investor confidence in the group's overall financial stability and borrowing capacity.
About Shilpa Medicare Limited (SHILPAMED)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when SHILPAMED files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track SHILPAMED — Free💡 Ask AI about this filing
📊 More SHILPAMED filings
- 🔴 Announcement — 7 July 2026 India Ratings upgraded Shilpa Medicare's bank loan facilities to IND AA- with a Positive outlook, wh...
- share transfer — 6 July 2026 Shilpa Medicare Limited received a SEBI-mandated share transfer agent certificate for the quarter en...
- 🔴 Financial Results — 3 July 2026 Shilpa Medicare Limited reported FY2026 revenue of [amount not verified] and net profit of [amount n...
- Financial Results — 25 June 2026 Shilpa Medicare Limited announced that its trading window will close on 1 July 2026 for all designat...
- Announcement — 24 June 2026 Shilpa Medicare announced that its subsidiary Shilpa Biologicals settled a legal dispute with Sartor...
🔥 Also filed on 16 July 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when SHILPAMED files new disclosures
Track SHILPAMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SHILPAMED — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research